Controversies in the treatment of elderly patients with newly diagnosed Glioblastoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 9, 2013, Pages 1165-1173

  Holdhoff, Matthias ^a   Chamberlain, Marc C ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; ELDERLY CARE; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84885090498     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0134     Document Type: Review

References (42)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14(Suppl 5):v1-49.
4. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-710. (Pubitemid 23133591)
5. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4:278-299.
6. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899. (Pubitemid 39330996)
7. Paszat L, Laperriere N, Groome P, et al. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:100-107. (Pubitemid 32758868)
8. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008;64:628-634.
9. Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 2009;33:17-22.
10. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol 2006;80:313-332. (Pubitemid 44782910)
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
12. Piccirilli M, Bistazzoni S, Gagliardi FM, et al. Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori 2006;92:98-103.
13. Sijben AE, McIntyre JB, Roldan GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008;89:97-103.
14. Gerstner ER, Yip S, Wang DL, et al. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009;73:1509-1510.
15. Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009;115:3512-3518.
16. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011;102:311-316.
17. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 2006.
18. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-715.
19. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012;131:1342-1350.
20. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812.
21. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
22. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-718.
23. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004;10:228-233. (Pubitemid 38114184)
24. Holdhoff M, Ye X, Blakeley JO, et al. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 2012;110:279-285.
25. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008;108:642-648. (Pubitemid 351498955)
26. Scott J, Tsai YY, Chinnaiyan P, Yu HH. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2011;81:206-210.
27. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008;88:97-103.
28. Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg 2013;118:786-798.
29. Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 2012;109:391-397.
30. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people-A randomised study. Acta Neurochir (Wien) 2003;145:5-10. (Pubitemid 36174074)
31. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994;34:62-66; discussion 66-67.
32. Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 2011;18:239-245.
33. Iwamoto FM, Cooper AR, Reiner AS, et al. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center experience (1997-2007). Cancer 2009;115:3758-3766.
34. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-1535. (Pubitemid 46588417)
35. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583-1588. (Pubitemid 41079795)
36. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 2013;39:350-357.
37. Combs SE, Wagner J, Bischof M, et al. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 2008;71:999-1005.
38. Fiorica F, Berretta M, Colosimo C, et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010;51:31-35.
39. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio [abstract]. Neuro Oncol 2012;14(Suppl 6):Abstract OT-03.
40. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol 2013;31(Suppl): Abstract 1.
41. Reyes-Botero G, Honnorat J, Chinot OL, et al. Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 2020.
42. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-926.